Huntingtons Disease Topics
The On-Topic Netowork

Huntingtons Disease > Antagonist


Antagonist
Antagonist
Antagonist
Antagonist
Antagonist

The following information is about Antagonist.

Antagonist Defined

a substance that blocks a receptor from binding to a neurotransmitter or hormone.

This definition is in context to Huntingtons Disease. See more contextual defintions for Antagonist.


Curis Announces Nature Publication Elucidating a Paracrine Mechanism of Action in Hedgehog-Expressing Tumors

Published August 27, 2008, 10:29 am, Centre Daily Times

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment, today announced the publication of preclinical data in Nature that support the premise that Hedgehog proteins play an important role in supporting tumor growth in Hedgehog-expressing solid tumors through a paracrine mechanism of action.

Full Story


'CNS Drug Discoveries: What the Future Holds 2008' Identifies 60 Drugs or Therapeutic Agents That Have the Potential ...

Published August 27, 2008, 8:40 am, Business Wire via Yahoo! Finance

DUBLIN, Ireland----Research and Markets has announced the addition of the "CNS Drug Discoveries: What the Future Holds 2008" report to their offering.

Full Story


Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial

Published August 27, 2008, 4:00 am, PR Newswire via Yahoo! Finance

Human Genome Sciences, Inc. today announced it has completed enrollment and initial dosing in BLISS-76, the second of two pivotal Phase 3 randomized clinical trials of LymphoStat-B® in patients with active systemic lupus erythematosus .

Full Story


Half of Surveyed Physicians Expect to Replace Between 6 Percent and 15 Percent of Their Sustiva Prescriptions with ...

Published August 26, 2008, 6:00 am, PR Newswire via Yahoo! Finance

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the expansion of labeling for Merck's Isentress to include use in treatment naive patients will significantly impact sales of the drug for HIV treatment as half of surveyed physicians expect to replace between six percent and 15 percent of their prescriptions for ...

Full Story


Human Genome Sciences Completes Enrollment In Randomized Phase 2 Trial Of HGS-ETR1 In Non-Small Cell Lung Cancer

Published August 23, 2008, 3:17 am, Medical News Today

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (mapatumumab) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

Full Story


Are you looking for additional Huntingtons Disease > Antagonist news? Try our new "Antagonist News Focus" area.

Off-site Antagonist Links, User Submitted

The following links have been collected through user bookmark submission in the Antagonist category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Thu Aug 28

Wed Aug 27

Thu Jul 24

Sat May 31

Thu May 8

Mon Apr 28

Thu Mar 27

Wed Mar 19

Tue Feb 19

If you would like to find additional social bookmark based links on the topic of we recommend the Open Tag Directory > Antagonist. If you would like to find related tags we recommend Tag Patterns > Antagonist

Off-site Antagonist Research Links

If you still need additional information on Antagonist then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Huntingtons Disease

If you know the Huntingtons Disease Term Name use the links below to quickly jump to your desired focus.



Bookmark Us

The On Topic Network

This website is part of The On Topic Network.

Thank You

Huntingtons-Disease.On-Topic.net was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.

Best Viewed With

License

Creative Commons License This work is licensed under Creative Commons.




Powered by Odin Assemble 2.5a